Clinical Trial Update: L-Arginine Treatment for Severe Vascular Fetal Intrauterine Growth Restriction: a Randomized Double Bind Controlled Trial (L Arginine in IUGR) [Phase 3]

View source ↗

Summary

A Phase 3 randomized, double-blind trial evaluating L-Arginine for severe vascular fetal intrauterine growth restriction was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intrauterine Growth Restriction

Drugs mentioned

• L-Arginine (L-Arginine)

Snippet

Sponsor: Nantes University Hospital | Conditions: Intra Uterine Growth Retardation | Phase 3 | Status: TERMINATED